Recent developments include Q2 2026 financial results showing a net loss but revenue exceeding expectations, positive clinical data for Anaphylm with plans for NDA resubmission, and stock price movements reflecting market reactions to these events.

• Aquestive Therapeutics reported a net loss for Q2 2026 but revenue topped expectations, indicating ongoing commercial activity despite losses [N1].
• Positive clinical data for Anaphylm were reported, with plans to resubmit the NDA in Q3, reflecting progress in regulatory strategy [N1].
• The company’s stock moved 6.6% higher in late June 2026, reflecting market interest in recent developments [N3].
• Q1 2026 earnings call highlighted narrower losses and strong revenue growth, with Anaphylm advancing in development [N4][N5][N6].
• Aquestive’s Q1 2026 results showed a loss but revenue beat expectations, supporting operational continuity [N7][N8].

Aquestive’s PharmFilm technology offers a differentiated oral film delivery platform with potential advantages in patient convenience and compliance. The company’s pipeline products, including Libervant and Anaphylm, address significant unmet medical needs in epilepsy and allergic reactions. Regulatory approvals and orphan drug exclusivities provide periods of market exclusivity. Manufacturing infrastructure and a broad patent portfolio support commercialization and protect intellectual property. Positive clinical data and regulatory progress for Anaphylm, along with strong liquidity, underpin the company’s operational capacity [S1][N6].

Aquestive faces regulatory and legal challenges, including a court ruling that converted Libervant’s FDA approval to tentative status, limiting market access. The company reported net losses and negative earnings per share in recent quarters, reflecting ongoing development and commercialization costs. Competition from established pharmaceutical companies with alternative drug delivery methods, including needle-based autoinjectors and nasal sprays, may limit market penetration. Manufacturing and supply chain dependencies, including single-source packaging suppliers, pose operational risks. Regulatory compliance and potential delays in product approvals or resubmissions, such as for Anaphylm, add uncertainty [S1][S2][N1].

Aquestive’s competitive advantages stem from its proprietary PharmFilm oral film technology platform, which provides unique drug delivery options for CNS and complex molecule therapeutics. The company’s extensive patent portfolio covering its technology, product candidates, and manufacturing processes offers intellectual property protection extending into the 2030s and 2040s. Manufacturing capabilities with cGMP-compliant facilities and regulatory approvals support product supply and quality. Additionally, orphan drug exclusivity granted for certain products like Libervant provides market protection in specific indications. However, the pharmaceutical industry’s rapid innovation, regulatory challenges, and competition from established companies with alternative drug delivery platforms present ongoing competitive pressures [S1].

• Regulatory Approval and Market Access Risks: Aquestive’s products are subject to extensive FDA and other regulatory approvals. Legal challenges and regulatory decisions, such as the court ruling affecting Libervant’s approval status, can delay or restrict market access.
• Competitive Risks: The company competes with established pharmaceutical and biotechnology firms offering alternative drug delivery platforms, including autoinjectors and nasal sprays, which may impact market share and pricing.
• Financial Risks: Aquestive has reported net losses and negative earnings per share, indicating ongoing expenses related to product development and commercialization that may affect financial stability.
• Manufacturing and Supply Chain Risks: Dependence on specific manufacturing facilities and single-source suppliers for packaging materials could disrupt production and supply continuity.
• Intellectual Property Risks: Patent challenges, administrative proceedings, or expiration of key patents could weaken the company’s competitive position and expose products to generic competition.

• Aquestive Therapeutics, Inc. develops and commercializes pharmaceutical products using its proprietary PharmFilm technology platform, which includes oral film dosage forms for CNS and complex molecule programs [S1].
• The company manufactures licensed products such as Suboxone, Emylif, Ondif, and Sympazan at two cGMP-compliant facilities in Portage, Indiana, with capacity to support current and pipeline products without additional infrastructure [S1].
• Aquestive’s product pipeline includes Libervant (diazepam buccal film) for acute repetitive seizures (ARS) and Anaphylm (dibutepinephrine sublingual film) for emergency treatment of allergic reactions including anaphylaxis [S1].
• Libervant received FDA approval for ARS patients aged 2-5 years with orphan drug exclusivity, but marketing was converted to tentative approval following a court ruling related to orphan drug exclusivity challenges [S1].
• Anaphylm is positioned as a non-needle, orally delivered epinephrine prodrug with clinical results comparable to autoinjectors like EpiPen and Auvi-Q, targeting Type I allergic reactions [S1].
• Aquestive holds a patent portfolio of at least 140 issued patents worldwide and over 110 pending applications covering PharmFilm technology, product candidates, and manufacturing processes, with patent expirations ranging from 2025 to 2045 [S1].
• The company’s AdrenaVerse technology platform for epinephrine prodrugs is covered by multiple patent families with protection extending potentially to 2045 [S1].
• Aquestive is subject to extensive FDA and other regulatory requirements including cGMP compliance, clinical trial oversight, and NDA approval processes [S1].
• As of June 30, 2026, Aquestive reported cash and equivalents of $98.49 million, current assets of $118.49 million, current liabilities of $16.48 million, resulting in a current ratio of 7.19 and a cash ratio of 5.98, indicating strong liquidity [S2].
• For Q2 2026, the company reported a net loss of $22.86 million and basic and diluted EPS of -$0.18 [S2].
• Recent news highlights include Q2 2026 financial results showing a loss but revenue exceeding expectations, positive clinical data for Anaphylm with plans for NDA resubmission, and ongoing regulatory and commercial developments [N1][N3][N6].
• Aquestive uses third-party CROs for clinical trial administration and relies on multiple suppliers for raw materials, with some single-source packaging foil suppliers [S1].
• The company faces competition from established pharmaceutical and biotechnology companies with various drug delivery platforms, including needle-based autoinjectors and nasal sprays for allergic reactions, and other epilepsy treatments [S1].
• Aquestive’s manufacturing facilities have passed inspections by FDA, DEA, TGA, and pharmaceutical companies for cGMP compliance and are registered with the DEA for Schedule II-V substances [S1].
• The FDA approval process for Aquestive’s products involves multiple stages including preclinical testing, IND submission, clinical trials, NDA submission, and facility inspections [S1].